SEC Form 4 · accession 0001567619-18-005098
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Nov 2, 2018
Accepted (ET)
Nov 5, 2018 · 5:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 2, 2018 | M | 1,500 | $17.86 | A | 289,790 | D | |
| Common StockF1 | Nov 2, 2018 | S | 1,500 | $97.88 | D | 288,290 | D | |
| Common Stock | holding | — | — | — | 182,201 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F2 | $17.86 | Nov 2, 2018 | M | 1,500 | D | Jun 17, 2009 | Dec 16, 2018 | Common Stock | 1,500 | 4,000 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 21, 2018.
- F2Reflects the number of options outstanding after the transactions from this specific stock option grant.